---
schema_version: "secwatch.filing_event.v1"
accession: "0001800943-23-000001"
form_type: "8-K"
ticker: "BRGX"
cik: "0001593184"
company_name: "BIOREGENX, INC."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:47:43.514668+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Findit enters definitive merger with BioRegenx; existing shareholders to hold 10% of voting stock

## Summary
- BioRegenx shareholders will receive common and preferred shares equivalent to 90% of Findit's voting securities.
- Findit Series A and B preferred shares (98.47% voting control) will be retired into treasury.
- Both parties agree to implement up to a 1-for-25 reverse stock split post-merger.
- Merger expected to close in Q1 2023, subject to shareholder and regulatory approvals.
- Combined entity will be renamed BioRegenx, Inc. and apply for a new ticker symbol.

## SEC filing metadata
- accession: 0001800943-23-000001
- form_type: 8-K
- ticker: BRGX
- cik: 0001593184
- company_name: BIOREGENX, INC.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593184/000180094323000001/0001800943-23-000001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593184/000180094323000001/fdit8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001800943-23-000001
- JSON: https://secwatch.observer/filing/0001800943-23-000001.json
- Plain text: https://secwatch.observer/filing/0001800943-23-000001.txt

## Key facts
- Material Agreements
  BIOREGENX, INC. entered into Merger Agreement with BioRegenx, Inc. (effective 2022-12-29).
  - Action: entry
  - Agreement: merger
  - Counterparty: BioRegenx, Inc.
  - Effective: 2022-12-29
  source text: On December 29, 2022, Findit, Inc. (the “Company” or “Findit”) announced it had entered into a definitive merger agreement (the “Merger Agreement”) with BioRegenx, Inc. (“BioRegenx”), a Nevada corporation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593184/000180094323000001/0001800943-23-000001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.